drugset / Trial / NCT01006161

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

NCT01006161

Phase 2 Withdrawn Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

Given the strong inhibition of SCH 527123 on neutrophil migration to sites of inflammation, there is a theoretical reason for its use in patients with severe asthma where neutrophils are thought to play a significant role in the pathophysiology of the disease.

Timeline

Start
2010-01
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator NAVARIXIN ANHYDROUS Small molecule

Indications